Posted by Michael Wonder on 08 Nov 2022
Libtayo (cemiplimab-rwlc) in combination with chemotherapy approved by the FDA as first-line treatment for advanced non-small-cell lung cancer
8 November 2022 - Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy alone, in a patient population with a wide range of disease characteristics.
Regeneron Pharmaceuticals today announced that the US FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer with no EGFR, ALK or ROS1 aberrations.
